Form 4: Annexon CMO Acquires Significant Equity and Options

Annexon's Chief Medical Officer, Jamie Dananberg, reported the acquisition of 56,250 restricted stock units and 225,000 stock options.

Summary

• Jamie Dananberg, Chief Medical Officer of Annexon, Inc. (ANNX), acquired 56,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) on February 19, 2026.
• The RSUs were acquired at a price of $0 and entitle the reporting person to receive one share of Common Stock for each RSU upon vesting.
• The RSUs vest in three annual installments, with the first 1/3rd vesting on February 19, 2027, and subsequent 1/3rd portions vesting on February 19, 2028, and February 19, 2029, subject to continuous service.
• Dananberg also acquired 225,000 stock options on February 19, 2026, with an exercise price of $5.1 per share.
• These stock options vest monthly over four years, with 1/48th of the shares vesting on each monthly anniversary from February 19, 2026, leading to full vesting on the fourth anniversary (February 19, 2030), subject to continuous service.
• The stock options have an expiration date of February 19, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it demonstrates continued insider commitment and aligns management's interests with long-term shareholder value, which is generally favorable.

Positives

• The acquisition of 56,250 Restricted Stock Units (RSUs) and 225,000 stock options by a Chief Medical Officer indicates continued commitment and alignment of interests with shareholders.
• Equity compensation incentivizes long-term performance and retention of key management personnel.

Future Outlook

The equity grants are structured with multi-year vesting schedules, indicating an expectation of continued service from the Chief Medical Officer and aligning their long-term incentives with the company's performance over the next several years.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units and stock options to key executives like a Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by linking their personal wealth to the company's stock performance and long-term success, which is crucial in a sector with extensive R&D cycles and regulatory hurdles.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's financial interests with the company's long-term stock performance, potentially fostering greater commitment to value creation.
• Employees: This compensation package for a senior executive may serve as a benchmark or signal for the company's overall approach to executive compensation and retention.

Next Steps

• The Restricted Stock Units (RSUs) will vest in three annual installments, starting February 19, 2027.
• The stock options will vest monthly over four years, with full vesting by February 19, 2030.
• The Chief Medical Officer's continuous service with Annexon, Inc. is required for the vesting of both RSUs and stock options.

Key Dates

Recommendation

A single Form 4 filing detailing routine equity compensation for an executive typically does not warrant a strong buy or sell recommendation. While insider ownership is generally a positive signal, this specific grant is a standard part of executive compensation and does not provide new fundamental information to significantly alter an investment thesis. Investors should 'hold' and consider this as a normal course of business.

Keywords

Annexon, ANNX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Chief Medical Officer, Jamie Dananberg